Close Menu

EPO

The EPO rejected arguments that were filed in opposition to the patent, which covers the use of CRISPR-Cas9 in cellular and non-cellular settings.

The European Patent Office appeals board upheld the decision made by the EPO after its initial review in 2018.

Oxford Nanopore had challenged the validity of the patent, EP3045542, which relates to DNA sample preparation for PacBio's circular consensus sequencing.

The patent claims strategies for identifying optimal breeding combinations of crop plants or cattle within a breeding population.

The Broad Institute also announced announced a setback in proceedings over a CRISPR patent application filed in Europe.

NEW YORK (GenomeWeb) – Benitec Biopharma this week announced that it is appealing the European Patent Office's recent revocation of a patent covering the company's core expressed RNAi technology, which had been successfully challenged by biotech firm Galapagos and agro-chemical giant BASF.

NEW YORK (GenomeWeb) – Benitec Biopharma last week announced that the European Patent Office has upheld its previous decision to revoke one of the company's core patents based on opposition filed by biotech firm Galapagos and chemical giant BASF.

Alnylam Pharmaceuticals this week announced that the European Patent Office has upheld a company patent related to chemically modified siRNAs and their ability to downregulate target genes via RNAi.

Marina Biotech this week said that the US Patent and Trademark Office has issued a notice of allowance for three of the company's patent applications related to its delivery technologies.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.